InvestorsHub Logo
Followers 13
Posts 1320
Boards Moderated 0
Alias Born 12/30/2016

Re: None

Wednesday, 06/07/2017 8:25:44 AM

Wednesday, June 07, 2017 8:25:44 AM

Post# of 3988
In the words of the Phase 2 trial Principal Investigator.......


"The data set created thus far further supports the potential of alidornase alfa becoming a gold standard treatment for all CF patients. I look forward to participating in the future development program for alidornase alfa with the goal of having the ability to offer alidornase alfa to patients dealing with this life shortening disease."




Read more: http://www.nasdaq.com/press-release/protalix-biotherapeutics-announces-phase-ii-clinical-trial-results-for-alidornase-alfa-in-cystic-20170607-00314#ixzz4jJoLzjEV
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PLX News